Hearts and Minds Investments (HM1) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
13 Jun, 2025Executive summary
Pre-tax investment portfolio increased 11.7% for the year ended 30 June 2024, driven by strong technology holdings and improved Conference Portfolio performance.
Total comprehensive income after tax was $53.5 million, down from $63.0 million in the prior year, reflecting lower other comprehensive income.
Share price rose from $2.26 to $2.58, narrowing the discount to pre-tax NTA to 17% and delivering a total shareholder return of 20% for FY24.
Fully franked dividends of 14 cents per share were paid, with an increased half-yearly dividend of 7.5 cents per share declared for October 2024.
$9.4 million was paid and $6.4 million provisioned for donations to Australian medical research organisations, in line with the company's philanthropic objectives.
Financial highlights
Total net investment income rose 45% to $83.4 million compared to $57.6 million last year.
Net income after tax increased 55% to $50.9 million from $32.7 million year-over-year.
Realised investment gains were $33.3 million; unrealised gains were $53.6 million.
Net asset value increased from $675.5 million to $697.4 million, after paying $32.0 million in dividends.
Basic and diluted EPS was 22.26 cents, up from 14.35 cents in the prior year.
Outlook and guidance
Board aims to maintain fully franked dividends, subject to cash reserves and franking credits.
Ongoing improvement in investment performance is expected to further narrow the share price discount to NTA.
Future performance will depend on portfolio returns and prevailing market conditions; no specific earnings guidance provided.
Latest events from Hearts and Minds Investments
- Flat portfolio returns and a major write-down led to a sharp drop in half-year profit.HM1
H1 202617 Feb 2026 - Strong returns, higher dividends, and active management drive performance and philanthropy.HM1
AGM 20243 Feb 2026 - Strong returns, rising dividends, and major medical research funding highlighted at AGM.HM1
AGM 202526 Nov 2025 - FY25 saw a 25.5% pre-tax return, 24% shareholder return, and $9.5M donated to medical research.HM1
H2 202528 Aug 2025 - Record half-year profit and robust portfolio returns drive NTA and dividend growth.HM1
H1 20255 Jun 2025